EICHORPublic-registry site landscape for NCT07752264, “A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy”, a Refractory Immune-mediated Necrotizing Myopathy study sponsored by Nanjing IASO Biotechnology Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07752264 (registry record) |
| Study title | A Phase I/II Study of Eque-cel in Subjects Withimmune-mediated Necrotizing Myopathy |
| Official title | An Open-label, Single-arm Phase I/II Clinical Study to Evaluate the Safety and Efficacy of Equecabtagene Autoleucel Injection (Eque-cel) in Subjects With Immune-mediated Necrotizing Myopathy |
| Sponsor | Nanjing IASO Biotechnology Co., Ltd. |
| Condition(s) | Refractory Immune-mediated Necrotizing Myopathy |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 4 |
| Intervention(s) | Equecabtagene Autoleucel Injection (Eque-cel) |
| Site countries | China |
Patient-friendly overview of this study: eichor.com/study/NCT07752264.
Eichor generates a preliminary site-risk snapshot for NCT07752264 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
